SAGE Sage Therapeutics Inc.

-3.81  -2%
Previous Close 187.41
Open 187.6
Price To Book 7.12
Market Cap 9,390,717,353
Shares 51,147,698
Volume 84,983
Short Ratio
Av. Daily Volume 391,995

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data due 4Q 2019 or 1Q 2020.
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
Phase 3 data due 2020.
Phase 2 Part A data due July 2019.
Bipolar depression
Phase 1 biomarker data due July 2019 with Huntington’s Disease Phase 1 cohort data due 2H 2019.
Huntington's disease
Phase 1 MAD data due July 2019. Top-line data due 2H 2019.
Essential tremor
Phase 3 data due 2020.
Major Depressive Disorder (MDD)

Latest News

  1. See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
  2. Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019
  3. Spiros Segalas' Top 5 Buys of the 2nd Quarter
  4. Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified?
  5. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  6. Sage Therapeutics to Host “Sage FutureCast” Webcast
  7. Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?
  8. Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
  9. Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
  10. Sage Therapeutics to Present at Goldman Sachs 40th Annual Global Healthcare Conference
  11. Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares
  12. Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
  13. Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?
  14. Ligand Grants Preclinical Candidate Rights to UK-based Firm
  15. Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
  16. Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT
  17. New England Venture Capital Association names 2019 NEVY Awards winners